XML 38 R27.htm IDEA: XBRL DOCUMENT v3.25.3
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2025
Stockholders' Equity Note [Abstract]  
Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding
The following is a summary of the Company's authorized and issued common and preferred stock as of September 30, 2025 and December 31, 2024:
   Outstanding as of
 AuthorizedIssuedSeptember 30, 2025December 31, 2024
Common Stock, par value $0.001 per share
600,000,000 53,571,675 53,571,675 36,099,991 
Series C Preferred Stock, par value $0.001 per share
1,091 1,091 
Schedule of Stockholders' Equity Note, Warrants or Rights
The following table summarizes the common stock warrants outstanding as of September 30, 2025 and December 31, 2024:
As of September 30, 2025As of December 31, 2024
Issued in Connection With:Exercise PriceExpiration
Date
Number of
Warrants
Common Stock Warrant LiabilityNumber of
Warrants
Common Stock Warrant Liability
December 2024 Offering$3.76 December 16, 202910,000,000 $13,415,241 10,000,000 $13,255,188 
July 2025 Offering - Series A$1.75 (1)13,857,144 $12,151,746 — — 
July 2025 Offering - Series B$1.75 July 7, 203014,285,715 $24,817,056 — — 
Total38,142,859 $50,384,043 10,000,000 $13,255,188 
(1) Earlier of (i) July 7, 2026 or (ii) 30 days after the date on which the Company first publicly discloses the U.S. Food and Drug Administration’s acceptance of a Biologic License Application for INO-3107.